Peter Rahko, MD
Cardiovascular Disease · Madison, WINPI 1063473981
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,190 of the $2,475 with a category attached, or 88.5%. Abbott accounts for 69.0% of it on its own, with 1 other manufacturer making up the rest.
Across 19 payments — averaging $130.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Amgen$766
Across 30 payments — averaging $3993.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$88K
- Merck$32K
What the payments were for
- Travel & lodging$2,19089%
- Food & beverage$28411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$1,222
How this compares
$2,475 in reported general payments places this provider in the 65th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 24 | $523,112 |
| EliquisApixaban | 131 | $172,770 |
| EntrestoSacubitril/Valsartan | 90 | $133,159 |
| CamzyosMavacamten | 15 | $123,130 |
| Metoprolol Succinate | 155 | $3,439 |
| Carvedilol | 184 | $2,489 |
| Ezetimibe | 25 | $1,908 |
| Eplerenone | 21 | $1,571 |
| Atorvastatin Calcium | 76 | $1,441 |
| Losartan Potassium | 78 | $1,121 |
| Furosemide | 121 | $1,081 |
| Digoxin | 37 | $959 |
| Lisinopril | 114 | $935 |
| Potassium Chloride | 38 | $891 |
| Spironolactone | 53 | $631 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Madison
- Sunil VasireddiMadison$36K
- Peter MarogilMadison$25K
- Colton ThompsonMadison$18K
- Lawrenshey CharlesMadison$15K
- Joseph LonginoMadison$8K
- David SloskyMadison$8K
- Meisam MoghbelliMadison$7K
- David KerblMadison$6K
- Subhashish AgarwalBrookfield$378K
- Lee BibloMilwaukee$280K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.